Tumour necrosis factor (TNF) blockers are currently recommended in existing guidelines. Recent trials strive to find other targets for treatment as numerous immunological events are involved in hidradenitis suppurativa (HS).
“Looking at biologics beyond TNF blockade, I will concentrate on IL-1α, ß and the possible role of IL-17 and IL-23,” said Prof. Brian Kirby (St. Vincent’s University Hospital, Ireland) . He emphasised that unlike in psoriasis, clinical trials will mostly show very high placebo response rates; one of the reasons that HS studies can be more difficult to interpret. In a not yet published phase 2 study without a placebo control group, bermekimab targeting IL-1α led to a positive Hidradenitis Suppurativa Clinical Response (HiSCR) at week 12 in 61% of the TNF-naïve patients [1,2]. A placebo-controlled phase 2 study of anakinra, an IL-1 receptor antagonist showed 78% HiSCR response at week 12 for the anakinra group vs 30% for placebo (P=0....
Please login to read the full text of the article.
If you have no account yet, please register now.
« Novel lupus classification will aid future research Next Article
What the future of keloid treatment could hold »